Chemovaccination with a late-liver-stage antimalarial induces durable immunity against malaria
Science · 2026
DOI: 10.1126/science.aea7605 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2026. Verfasst von Ryan W J Steel und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. Hauptthemen laut MEDLINE: Antibodies, Protozoan, Aspartic Acid Endopeptidases, Liver, Malaria Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 94 Literaturangaben. Gefördert von: Wellcome, National Health and Medical Research Council, Merck Sharpe & Dohme.
Abstract (Originalsprache)
Plasmodium falciparum sporozoite vaccines, in which parasites are attenuated at the liver stage, provide high efficacy but require complex manufacture and intravenous administration of high sporozoite doses. We found that a single low-dose P. berghei sporozoite exposure (intravenous or mosquito bite) and treatment with a plasmepsin IX and X (PMIX/X) inhibitor, either WM382 or MK-7602, that produced “chemo-attenuated liver merozoites” (CALM) induced sterile immunity in mice for up to 21 months. Protection involved anti–circumsporozoite protein (CSP) antibodies and CD8 + T cells, including liver-resident memory subsets that recognized diverse antigens (SERA1, RPL6, GAP50, RNT, PHIST, S20, and RBP). WM382 also attenuated P. falciparum liver merozoites, and conservation of PMIX/X active sites supports pan- Plasmodium potential for preventing malaria. CALM vaccination merits clinical evaluation, including by natural mosquito exposure if long-acting injectable PMIX/X inhibitor formulations prove feasible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
- Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
- Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute, Parkville, VIC, Australia.
- Department of Molecular Medicine, University of New South Wales and UNSW RNA Institute, School of Biomedical Sciences, Faculty of Medicine and Health, Sydney, NSW, Australia.
- Merck & Co., Inc., West Point, PA, USA.
ORCID-Profile: Ryan W J Steel, Robyn McConville, Amelia Ford, Daniel Fernandez-Ruiz, Lauren E Holz, William R Heath, John A McCauley, David B Olsen, Justin A Boddey
Förderung
- Wellcome
- National Health and Medical Research Council
- Merck Sharpe & Dohme
- NHMRC Ideas
- Investigator L1
Zitieren
APA
Steel, R. W. J., Chua, Y. C., Abdalla, W. A. I., McConville, R., Ford, A., Caiazzo, S., Hesping, E., Fernandez-Ruiz, D., Holz, L. E., Heath, W. R., McCauley, J. A., Olsen, D. B., & Boddey, J. A. (2026). Chemovaccination with a late-liver-stage antimalarial induces durable immunity against malaria. Science. https://doi.org/10.1126/science.aea7605
Vancouver
Steel RWJ, Chua YC, Abdalla WAI, McConville R, Ford A, Caiazzo S, et al. Chemovaccination with a late-liver-stage antimalarial induces durable immunity against malaria. Science. 2026. doi:10.1126/science.aea7605
BibTeX
@article{Steel2026,
author = {Steel, Ryan W J and Chua, Yu Cheng and Abdalla, Waail A I and McConville, Robyn and Ford, Amelia and Caiazzo, Sabrina and Hesping, Eva and Fernandez-Ruiz, Daniel and Holz, Lauren E and Heath, William R and McCauley, John A and Olsen, David B and Boddey, Justin A},
title = {Chemovaccination with a late-liver-stage antimalarial induces durable immunity against malaria},
journal = {Science},
year = {2026},
doi = {10.1126/science.aea7605}
}
EUVIMED